Galectin Therapeutics Stock Performance
| GALT Stock | USD 1.54 0.05 3.14% |
Galectin Therapeutics holds a performance score of 16 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -0.17, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Galectin Therapeutics are expected to decrease at a much lower rate. During the bear market, Galectin Therapeutics is likely to outperform the market. Use Galectin Therapeutics downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Galectin Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Galectin Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting essential indicators, Galectin Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:6 | Last Split Date 2012-03-23 |
1 | Acquisition by Freeman Kevin D of 10000 shares of Galectin Therapeutics at 0.8134 subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Shlevin Harold H. of 6500 shares of Galectin Therapeutics at 1.16 subject to Rule 16b-3 | 12/30/2024 |
3 | Galectin Therapeutics Highlights Promising NAVIGATE Trial Results - TipRanks | 01/13/2025 |
4 | Acquisition by Omenn Gilbert S of 60000 shares of Galectin Therapeutics at 1.23 subject to Rule 16b-3 | 01/23/2025 |
5 | Galectin Therapeutics 8-K Filing Reveals Positive Results from NAVIGATE Trial | 01/24/2025 |
6 | Acquisition by Callicutt Jack W of 60000 shares of Galectin Therapeutics subject to Rule 16b-3 | 01/28/2025 |
7 | Acquisition by Jamil Khurram of 40000 shares of Galectin Therapeutics subject to Rule 16b-3 | 02/06/2025 |
8 | Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. announced significant finding... | 02/21/2025 |
9 | Disposition of 56420 shares by Joel Lewis of Galectin Therapeutics at 1.57 subject to Rule 16b-3 | 03/03/2025 |
10 | Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks | 03/05/2025 |
11 | Acquisition by Freeman Kevin D of 2500 shares of Galectin Therapeutics at 2.98 subject to Rule 16b-3 | 03/07/2025 |
12 | Galectin Therapeutics Inc.s market cap up US10m last week, benefiting both retail investors who own 54 percent as well as insiders | 03/14/2025 |
13 | Acquisition by Amelio Gilbert F of 50000 shares of Galectin Therapeutics at 1.72 subject to Rule 16b-3 | 03/18/2025 |
14 | Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens | 03/19/2025 |
| Begin Period Cash Flow | 18.6 M |
Galectin |
Galectin Therapeutics Relative Risk vs. Return Landscape
If you would invest 84.00 in Galectin Therapeutics on December 24, 2024 and sell it today you would earn a total of 75.00 from holding Galectin Therapeutics or generate 89.29% return on investment over 90 days. Galectin Therapeutics is currently generating 1.2202% in daily expected returns and assumes 5.8428% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Galectin, and 76% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Galectin Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galectin Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Galectin Therapeutics, and traders can use it to determine the average amount a Galectin Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2088
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GALT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.84 actual daily | 52 52% of assets are less volatile |
Expected Return
| 1.22 actual daily | 24 76% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Galectin Therapeutics is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Galectin Therapeutics by adding it to a well-diversified portfolio.
Galectin Therapeutics Fundamentals Growth
Galectin Stock prices reflect investors' perceptions of the future prospects and financial health of Galectin Therapeutics, and Galectin Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Galectin Stock performance.
| Return On Equity | -37.28 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 179.54 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Price To Earning | (4.21) X | ||||
| Price To Book | 207.70 X | ||||
| EBITDA | (202 K) | ||||
| Net Income | (41.07 M) | ||||
| Cash And Equivalents | 15.83 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 71.81 M | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | (1.52) X | ||||
| Cash Flow From Operations | (32.97 M) | ||||
| Earnings Per Share | (0.73) X | ||||
| Market Capitalization | 99.79 M | ||||
| Total Asset | 28.2 M | ||||
| Retained Earnings | (354.37 M) | ||||
| Working Capital | 12.03 M | ||||
| Current Asset | 26.4 M | ||||
| Current Liabilities | 1.36 M | ||||
About Galectin Therapeutics Performance
Assessing Galectin Therapeutics' fundamental ratios provides investors with valuable insights into Galectin Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Galectin Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (3.50) | (3.32) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | 0.78 | 0.74 |
Things to note about Galectin Therapeutics performance evaluation
Checking the ongoing alerts about Galectin Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Galectin Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Galectin Therapeutics is way too risky over 90 days horizon | |
| Galectin Therapeutics may become a speculative penny stock | |
| Galectin Therapeutics appears to be risky and price may revert if volatility continues | |
| Galectin Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (41.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Galectin Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens |
- Analyzing Galectin Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Galectin Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Galectin Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Galectin Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Galectin Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Galectin Therapeutics' stock. These opinions can provide insight into Galectin Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.